UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/922,233	08/03/2001	Simon Erani	4061.007	8232

7590 09/10/2002

Morris E. Cohen
Suite 217
1122 Coney Island Avenue
Brooklyn, NY 11230-2345

EXAMINER	
BERMAN, ALYSIA	
ART UNIT	PAPER NUMBER
1617	

DATE MAILED: 09/10/2002 5

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER
	5

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Requirement for Information

Applicant and the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application.

The information is required to identify products and services embodying the disclosed subject matter of retinyl palmitate polypeptide, ascorbylmethylsilanol pectinate, tocopheryl polypeptide, cholecalciferol polypeptide and niaciniamide polypeptide and identify the properties of similar products and services found in the prior art.

In response to this requirement, please provide a list of keywords that are particularly helpful in locating publications related to the disclosed art of retinyl palmitate polypeptide, ascorbylmethylsilanol pectinate, tocopheryl polypeptide, cholecalciferol polypeptide and niaciniamide polypeptide.

In response to this requirement, please provide copies of each publication which any of the applicants authored or co-authored and which describe the disclosed subject matter of retinyl palmitate polypeptide, ascorbylmethylsilanol pectinate, tocopheryl polypeptide, cholecalciferol polypeptide and niaciniamide polypeptide.

In response to this requirement, please provide the title, citation and copy of each publication that any of the applicants relied upon to develop the disclosed subject matter that describes the applicant's invention, particularly as to developing a composition comprising at least two of retinyl palmitate polypeptide, ascorbylmethylsilanol pectinate, tocopheryl polypeptide, cholecalciferol polypeptide and niaciniamide polypeptide. For each publication, please provide a concise explanation of the reliance placed on that publication in the development of the disclosed subject matter.

In response to this requirement, please state whether any search of prior art was performed. If a search was performed, please state the citation for each prior art collection searched. If any art retrieved from the search was considered material to demonstrating the knowledge of a person having ordinary skill in the art to the disclosed a composition comprising at least two of retinyl palmitate polypeptide, ascorbylmethylsilanol pectinate, tocopheryl polypeptide, cholecalciferol polypeptide and niaciniamide polypeptide, please provide the citation for each piece of art considered and a copy of the art.

In response to this requirement, please provide the names of any products or services that have incorporated the claimed subject matter.

In responding to those requirements that require copies of documents, where the document is a bound text or a single article over 50 pages, the requirement may be met by providing copies of those pages that provide the particular subject matter indicated in the requirement, or where such subject matter is not indicated, the subject matter found in applicant's disclosure.

The fee and certification requirements of 37 CFR 1.97 are waived for those documents submitted in reply to this requirement. This waiver extends only to those documents within the scope of this requirement under 37 CFR 1.105 that are included in the applicant's first complete communication responding to this requirement. Any supplemental replies subsequent to the first communication responding to this requirement and any information disclosures beyond the scope of this requirement under 37 CFR 1.105 are subject to the fee and certification requirements of 37 CFR 1.97.

The applicant is reminded that the reply to this requirement must be made with candor and good faith under 37 CFR 1.56. Where the applicant does not have or can readily obtain an item of required information, a statement that the item is unknown or cannot be readily obtained will be accepted as a complete reply to the requirement for that item.

This requirement is subject to the provisions of 37 CFR 1.134, 1.135 and 1.136 and has a shortened statutory period of 2 months. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

RUSSELL TRAVERS
PRIMARY EXAMINER
GROUP 1200

Alysia Berman
Patent Examiner
August 26, 2002